BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

VAXXINITY FORMERLY KNOWN AS COVAXX — Receipts Report

LD-2 disclosure · 3rd Quarter - Amendment

VAXXINITY FORMERLY KNOWN AS COVAXX

via MICHAEL BEST STRATEGIES LLC

3rd Quarter (July 1 - Sep 30) · 2021Posted Dec 29, 2021Filing document ↗LDA record ↗

Income$70Kfee reported

Client

Name: VAXXINITY FORMERLY KNOWN AS COVAXX
Description: medical manufacturing
Location: Texas · United States of America

Registrant

Firm: MICHAEL BEST STRATEGIES LLC
Description: Government Relations Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
issues relating to vaccine development, expedite FDA Emergency Use Authorization
LobbyistsDENISE BODE · ALEXANDER ANGELSON · OLIVIA PAIGE IMHOFF · LUCIA ALONZO · ms TAMI JACKSON BUCKNER
Covered position (ALEXANDER ANGELSON): Special Assistant to the President, White House Legislative Affairs
Covered position (OLIVIA PAIGE IMHOFF): Deputy Associate Director, Executive Office of the President
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.